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We thank Drs Nee and Lembo1 for their editorial com-
menting on our article.2 We would like to respond by
pointing out the need for a treatment for irritable bowel
syndrome with diarrhoea (IBS-D) that addresses the
increased frequency of loose, watery stools and the
increased pain caused by stress.
Stress-induced diarrhoea and pain are regarded as key
factors in IBS, although they are not much discussed. They
are targets for the treatment of IBS with behavioural
approaches that focus on the use of paced respiration and
relaxation training to regulate stress, and a recent review
of these techniques was published in the stress chapter of
the Rome IV project.3 Unfortunately, these behavioural
techniques are time-consuming, and are not widely avail-
able. A new drug such as ONO-2952,1 if conﬁrmed in sub-
sequent studies, would make it possible for this aspect of
IBS to be addressed by primary care practitioners.
We look forward to follow-up studies which would make
it possible to select patients who are uniquely responsive to
this category of drug. In animal studies, rats were selected
who were selectively trained to avoid fear-producing shocks,
and these subjects were uniquely responsive to the drug;
however, in the human study reported to date, no such
selection of subjects was done to minimise recruitment
problems. New studies could include patients who are
selected for their responsiveness to the effects of anxiety.
Future studies should also test higher doses of ONO-
2952 to identify whether the drug is uniquely associated
with actions in the brain or has peripheral effects as well.
To date, there is no reason to expect the highest dose of the
study drug to be 60 mg/day, but more data are needed on
higher doses. Thus, there is considerable room for future
research to expand on this unique preliminary study.
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The role of dietary ﬁbres for management of functional
bowel disorders remains unclear. Recent meta-analyses
suggest soluble ﬁbres are beneﬁcial in irritable bowel
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syndrome.1, 2 However, supplementation with soluble
ﬁbres that are classiﬁed as prebiotic (i.e. galacto-oligosac-
charides and inulin-type fructans) are less well studied.
One randomised controlled trial (RCT) has suggested
galacto-oligosaccharide supplementation may improve
abdominal pain in IBS.3 In contrast, reducing colonic
hydrogen production by restriction of fermentable sub-
strates is beneﬁcial to gastrointestinal symptoms,4, 5 but
may also lead to potentially deleterious alterations in the
microbiota.6, 7
With this paradox in mind, Mego et al. designed a 3-
week uncontrolled pilot study to assess the effect of
galacto-oligosaccharide supplementation on symptoms,
intestinal gas production and the microbiota in 20 healthy
subjects.8 The number and volume of anal gas evacua-
tions signiﬁcantly increased over the ﬁrst 2 days of sup-
plementation compared with baseline. However, these
returned to baseline levels at the end of supplementation.
There was no change in gastrointestinal symptoms and,
although there were no differences in speciﬁc bacterial
taxa throughout the study, volume of gas evacuated at
the end of supplementation inversely correlated with
abundances of certain intestinal bacteria including Lach-
nospiraceae, which is known to be fermentative.
The apparent functional adaptation of the colonic
microbiota to the administered prebiotic is interesting
given the improvement in gastrointestinal symptoms after
4 weeks of supplementation of the same product in IBS
mentioned above.3 However, gas production and early
symptom responses to the prebiotic were not measured in
the study by Silk et al., and therefore it is not known
whether the same adaptation occurred in these IBS
patients. Given the evidence of dysbiosis in patients with
IBS,9 and the inter-individual differences in diet-induced
microbiota alterations here8 and in previous work,10 it
would be of interest to repeat this intervention in a
controlled trial of patients with IBS. Insight into the
magnitude and duration of increased luminal gas and GI
symptoms on initial exposure to prebiotics in functional
bowel disorders would be advantageous, considering that
early symptom exacerbation might discourage compliance
to this type of therapy.
A difﬁculty in interpreting trials of this nature is the
confounding posed by the potential variability in dietary
intake of participants. The authors appear to have
attempted to address this issue by standardising the diet
throughout the outcome measurement periods. This could
also, however, be considered a limitation of this study as it
is unknown what effect the simultaneous alteration of
dietary intake had on ﬁndings independently of the prebi-
otic itself, and this is rightly acknowledged by the authors.
Evidence for the effectiveness of prebiotics for man-
agement of functional gastrointestinal symptoms remains
limited. This study, however, suggests further evaluation
of a speciﬁc galacto-oligosaccharide is warranted, with
early and regular monitoring of symptom response. A
key strength of this study was inclusion of clinical, phys-
iological and microbiota endpoints, with the latter sur-
prisingly often lacking in trials of pre- and probiotic
supplementation, but likely critical for an understanding
of their mechanisms of action.
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